Mohammad AskarPublic working copy · medical review pending

Glaucoma · 007

Childhood glaucoma: recognition, assessment and treatment

Complete lecture with teaching cases, comparison table and explicit source questions.

Working copy published: 2026-11-06T03:47:16+01:00. Source, translation and medical checks remain open. Limitations are stated in the text and references. Editorial text version: 2026-11-03 04:08 CET.

Assess pressure, structure and serial change together. PCG usually needs early surgery; visual development needs additional targeted care.

Terminology and translation status

Original terms are retained and explained. Inspected UMD entries and pending translations are documented in the terminology ledger; Arabic terminology is not yet finally approved.

01Clinical overview

Childhood glaucoma comprises several disorders. Assess pressure, cornea, axial length and optic nerve together. In infants, raised pressure can enlarge the eye and impair visual development. 1 2

Hydrophthalmos / buphthalmos describes pressure-related enlargement of the young eye. AAO BCSC 2024–2025 Section 10 text, p 193, describes corneal distensibility until approximately 3–4 years and scleral distensibility until 10 years. These are developmental descriptions, not sharp exclusion thresholds. Assess growth against age and serial findings. 2 8 12

Primary congenital glaucoma (PCG) involves abnormal outflow development and usually requires early surgery. Medication may be an appropriate initial approach in JOAG, uveitis or glaucoma following cataract surgery. Do not transfer adult treatment algorithms unchanged. 1 2

The original lecture cautions against teaching a proven physical “Barkan membrane” as the sole cause. It describes trabeculodysgenesis, anterior iris insertion and Schlemm canal abnormalities. Retain the term as a historical model; surgery improves outflow rather than simply dividing an established membrane. 8

02Classification, epidemiology and genetics

Assess age and presentation

PCG: neonatal onset 0–1 month; infantile onset >1 to 24 months; late onset or recognition >2 years. Rare spontaneously non-progressing forms are described. They do not justify a routine delay when findings are suspicious. Age at diagnosis and actual onset differ. 1

Juvenile open-angle glaucoma (JOAG). The lecture uses 4–40 years; EGS6 describes a typical range of 4–35 years and >4 years in its classification. Definitions differ. JOAG may involve myopia, very high pressure and unnoticed field damage. Corneal enlargement need not be present. 1 8

EGS6 reports approximately 70% bilateral disease and 65% male patients in PCG. The lecture gives 25% neonatal onset, >75% diagnosed in year one and approximately 50% between months 1 and 12. The latter figures remain lecture estimates without an identified primary cohort, not universal frequencies. 1 8

Clarify cause and family risk

Retain CYP1B1, LTBP2 and ANGPT1/TEK; MYOC is relevant in JOAG. The AAO textbook text describes up to 40% autosomal recessive cases. Its 2% on p 192 concerns offspring of an affected patient without a family history, not siblings. This clarifies the ambiguous lecture attribution. Individual counselling requires pedigree and variant assessment. 1 2 8 12

Distinguish non-acquired ocular anomalies, non-acquired systemic disease/syndromes, acquired causes and glaucoma following cataract surgery. Examples include uveitis, trauma, steroid effects and lens-related mechanisms. Gonioscopy and associated findings help establish the mechanism before treatment. 1 2

03Clinical diagnosis and progression

Examine symptoms and cornea

Epiphora, photophobia, blepharospasm. Tearing, light sensitivity and involuntary eyelid closure form the classic triad. Absence of symptoms does not exclude disease. Corneal clouding or unusual eye enlargement requires urgent paediatric ophthalmic assessment. 1 3

EGS6 criteria flag ≥11 mm in a newborn, >12 mm in the first year and >13 mm regardless of age. This is not “>11 mm for every child under one year”. A normal diameter does not exclude glaucoma. Serial change and other findings remain essential. 1

Haab striae are breaks in Descemet membrane associated with stretching. Record their location, oedema, clarity and diameter. Consider nasolacrimal obstruction, keratitis, birth trauma, megalocornea and corneal dystrophies in the differential. 1 3

Assess pressure, structure and serial change together

Examination under anaesthesia (EUA) is useful when an adequate awake examination is not possible. Tono-Pen, Perkins, pneumotonometry and rebound tonometry are distinct methods. Record device, cooperation, anaesthetic, timing and airway interventions; anaesthesia is not required for every examination. 1 2 3

>21 mmHg appears in published criteria; it is neither sufficient proof nor a safe exclusion threshold. Many anaesthetics lower readings, while crying and squeezing raise them. The lecture estimate of a 10–20% decrease is not a universal conversion factor. Do not routinely add that percentage or a CCT correction. 1 2 8

Assess the rim, focal notches and progression. C/D asymmetry ≥0.2 with similar disc size is concerning; C/D >0.3 alone is not a universal diagnostic criterion. OCT requires quality control and age-appropriate interpretation. Use fields when cooperation permits and repeat suspicious defects. 1 2

Compare axial length and cycloplegic refraction with earlier values and age-related growth. Excessive elongation or myopic shift may indicate inadequate control. Amblyopia from opacity, anisometropia or strabismus needs its own treatment. Pressure control alone does not guarantee good visual development. 1 2

EGS6 Table II.4, p 119, prints <21 mmHg on two occasions for suspected glaucoma. In contrast, AAO BCSC 2024–2025 Table 11-1, p 188, specifies >21 mmHg on two separate occasions without pressure-related damage. The 2024 CGRN algorithm also uses >21 and requires reproducibility. 1 8 9 12

It is not an original 2013 document. The source discrepancy remains unresolved; no official EGS erratum is claimed. Pressure-only suspicion is not a glaucoma diagnosis. 1 8 9 12

04Differential diagnosis and teaching cases

Teaching cases paraphrased from the exported lecture; no patient images, names or calendar dates. A case decision does not establish efficacy.

Cloudy cornea: CHED, glaucoma or both?

Congenital hereditary endothelial dystrophy (CHED) can mimic glaucoma through corneal clouding. Normal diameter and apparently normal pressure do not exclude coexisting glaucoma. Check Haab striae, disc, growth and progression; pachymetry, ultrasound biomicroscopy (UBM) or Pentacam provide additional information. 1 7 8

UBM can add anterior-segment and corneal information through cloudy media. Pentacam thickness maps need adequate acquisition quality and cooperation. Both supplement clinical assessment; neither replaces tonometry, disc assessment or growth monitoring. 8

IC3D edition 3 (2024): CHED1 was removed as a distinct entity; previously described dominant families probably had PPCD. Former recessive CHED2 is termed CHED. The lecture values of 1100–1200 µm describe markedly thickened corneas in cases, not a diagnostic threshold. UBM or a uniform thickness map alone does not prove the diagnosis. 7 8

Teaching case: structural progression despite modest measured pressure. The exported lecture case initially had readings of 17/16 mmHg and approximately 900 µm corneal thickness. Axial length and disc change increased over six weeks, prompting surgery. Clearing after bilateral treatment was described. Teaching point: repeated measurement conditions and structural progression matter more than an isolated “normal” reading. Six weeks is not a recommended interval for other children. 8

Teaching case: persistent thickening after pressure control. A second lecture case had pressure ranges of 20–27 and 22–33 mmHg with approximately 1200 µm corneal thickness. Clarity improved after glaucoma surgery but marked, relatively uniform thickening persisted. The lecturer discussed CHED plus glaucoma. This is a teaching-case interpretation without histology or genetic confirmation inspected here; do not treat PCG and CHED as mutually exclusive. 8

Check other causes and syndromic findings

JOAG teaching case: high pressure with a quiet anterior segment. The lecture describes a young adult with readings around 60 mmHg, still 36/52 mmHg on several medications, and advanced OCT/field damage. The lecturer chose deep sclerectomy and reported pressure around 9 mmHg at about one year. This is not a comparative study or evidence of superiority over trabeculectomy or implants. Quiet-looking eyes do not exclude high pressure. 8

Axenfeld-Rieger: assess posterior embryotoxon, iridocorneal strands, iris changes and possible dental/facial findings. The lecture gives 50% glaucoma risk; EGS6 gives 50–75%. Later onset remains possible. Peters anomaly can involve central opacity and iridocorneal or lenticulocorneal adhesions; its lecture figure of 50% requires a defined cohort. 1 8

ICE syndrome is not the typical first explanation for bilateral dysgenesis in a young child. 1 8

Distinguish PAX6-related aniridia from an adjacent WT1 deletion. WAGR comprises Wilms tumour, aniridia, genitourinary anomalies and developmental impairment. The existing blanket “50% WAGR” statement is unsupported. Arrange genetics and paediatric tumour surveillance; in sporadic aniridia do not wait for later glaucoma before addressing surveillance. 1 2

Sturge-Weber and the “tomato-catsup” fundus. The descriptive lecture term refers to a red fundus appearance with diffuse choroidal vascular involvement; it is not obligatory. Early angle abnormalities and later elevated episcleral venous pressure can contribute. Consider choroidal effusion/haemorrhage and hypotony before surgery. Lecture figures of 30–70% glaucoma and 60/40% early/late presentations remain cohort-dependent and not primary-verified here. 2 8

Sturge-Weber teaching case. The lecture describes an affected eye with approximately 28–30 mmHg, corneal enlargement and choroidal involvement. Angle surgery proceeded despite prominent intraoperative vessels; approximately 10 mmHg and improved clarity were later reported. This was a case-specific decision, not a general requirement for trabeculotomy or prohibition of drainage implants. 8

Monitor long term after cataract surgery

IATS: glaucoma after infantile cataract surgery. Secondary analysis of a randomised trial: 114 infants with unilateral cataract, surgery at 1–6 months, primary IOL versus aphakia/contact lens. At age 10.5 years, 110 were examined and glaucoma status was available for 106. Ten-year risk: glaucoma 22% (95% CI 16–31), glaucoma plus suspect 40% (32–50). Keep these endpoints separate. 4

Glaucoma risk did not differ significantly: contact lens 23% (14–37) versus IOL 21% (13–35); HR 1.0 (0.5–2.3). This does not establish equivalence. Small sample, no required study visits between years 5 and 10 and non-standardised glaucoma treatment limit interpretation. It establishes neither the best glaucoma operation nor risk for all children; lifelong surveillance remains necessary. 4

05Surgical treatment strategies

Select angle surgery and interpret success

Goniotomy (ab interno) generally requires an adequate view. Trabeculotomy (ab externo) accesses Schlemm canal externally and can be used with an opaque cornea. Consider procedure, severity, prior surgery and centre experience together. Diameter alone does not select the operation. 1 2

The lecture quotes 70–90% in Western populations, <50% in the Middle East and sometimes ≤25% with neonatal onset. It also uses <13, 13–16 and >16 mm as surgical prognosis groups. Without cohort, severity, success definition and follow-up these are not reliable individual predictions. 8

Severe early disease can differ; origin alone is not a surgical algorithm. 8

AAO BCSC 2024–2025 p 213 gives 70–80% for angle surgery in PCG diagnosed at 3–12 months, explicitly including repeated procedures. This is not a single-operation rate and does not validate the lecture comparison “West 70–90% versus Middle East <50%”. Underlying series, success definitions and time horizons were not fully appraised here. 12

Systematic review, search to 27.04.2020: 16 trials, 446 children and 587 PCG eyes, under age five. Microcatheter-assisted 360° versus conventional trabeculotomy at 12 months: mean IOP difference −1.77 mmHg (95% CI −2.92 to −0.63; 99 eyes), success RR 1.54 (1.20–1.97). Moderate certainty for these outcomes; hyphema may be more frequent. Lifetime visual or quality-of-life superiority is unproven. 5

For combined trabeculotomy/trabeculectomy versus trabeculotomy, the review found a one-year IOP difference of 0.27 mmHg (−0.74 to 1.29; 88 eyes) and success RR 1.01 (0.90–1.14; 102 eyes). Very low certainty establishes neither superiority nor equivalence. Bleb risks and follow-up burden remain. Most comparisons are small; several analysed paired eyes without adequate correlation adjustment. 5

Appraise modified procedures and case series

“Enhanced by Deep Sclerectomy” / “Window-Defect”. The lecturer describes deeper scleral dissection to locate Schlemm canal and modified lateral opening while preserving central tissue. An exact operative description requires video/slide confirmation. Lecture estimates of 11–15% or 4–24% unidentifiable canal and the proposed genotype link remain source-pending. 8

Viscocanalostomy and further lecture numbers. The cited pilot by Noureddin et al. (2006), DOI 10.1136/bjo.2006.096388, compared eight children with bilateral PCG, one eye per procedure. The export quotes approximately 34→15.6 mmHg for trabeculotomy and 32→12 mmHg for viscocanalostomy; timing and dispersion require original verification. Eight pairs cannot establish superiority. 8 10

Preserved lecture figures: 81% combined-surgery success; 42% with IOP <18 mmHg without drops; 72% without further intervention; mean 2.5±2.4 operations, 2.8±1.9 for cyclodestructive procedures, sometimes 1–8 sessions. Rates declining from 90→74% and 67→54% are also quoted. Original tables, denominators and time points are missing. These are source questions, not current counselling estimates. 8

Identified 2007 series: medication is not surgery. Alsheikheh et al.: retrospective 43 patients/68 eyes operated in 1990–2002; 36 PCG and 7 secondary cases. Follow-up 57.3±36.8 months (6–161). After one operation, 29/68 eyes (42.6%) had IOP ≤18 mmHg without medication. After the final operation, 49/68 (72.1%) needed no further medical treatment. 16

This corrects the preceding lecture rendering “72% without further intervention”; ≤18 also differs from <18. Mean 2.5±2.4 operations per eye (1–11). The abstract provides no confidence intervals or controlled procedure ranking. 16

Plan implant size, clearance and follow-up

Ahmed valve FP7 / FP8. The lecture gives FP7 16 mm, FP8 10 mm and areas 184/96 mm². Separately, the IFUs, Rev B 03/2025, p 17, show FP7 plate length 16 mm, overall width 13 mm, area 184 mm²; FP8 11 mm, 11 mm and 102 mm². 8 11

Maximum overall length is 41.4/36.4 mm and maximum thickness 2.1 mm for each. Do not retrospectively label historical 96-mm² study devices as 102 mm². The date and nature of a model change are not established here. The lecture AL <21 mm rule remains unverified; axial length alone does not determine selection. 8 11

The lecture illustrates sizing in a markedly elongated eye and later fibrosis with entrapped Tenon tissue. These remain important: pressure elevation after implantation may require reassessment and revision. An implant does not remove follow-up needs. The quoted 40–60% success rate and Freedman/Margeta calculator are not verified here as a validated paediatric selection rule without version, endpoint and timeline. 8

The export quotes axial length 31 mm in a markedly enlarged eye. A separate calculator example uses AL 21 mm, cornea 12 mm and limbal distance 8 mm; 6.3 mm rather than 8 mm is discussed to retain optic nerve clearance of 2 mm. 8

These remain unconfirmed lecture numbers. Without original geometry, model revision and validated calculation they are not implantation instructions. 8

Implant clearance: anatomical model, not clinical safety proof. Margeta et al. 2017 studied 15 paediatric autopsy eyes: 10 for derivation, 5 for validation; axial lengths 15–24 mm. The model estimates limbus-to-optic-nerve distance from ocular dimensions and implantation quadrant. R² 0.92–0.98 describes agreement, not a demonstrated reduction in clinical complications. Small post-mortem validation: no universal AL-21-mm rule or verified operative protocol. 17

Reassess after failed angle surgery

2026 primary study: repeat trabeculotomy. Prospective nonrandomised comparison after failed PCG angle surgery: 164 eyes, 82 per group; viscocanalostomy plus repeat trabeculotomy versus repeat trabeculotomy. Follow-up 30.36±13.38 months. Success: IOP 6–21 mmHg and ≥20% reduction. Failure 26/82 (31.7%; 95%CI 22.4–42.3) versus 31/82 (37.8%; 27.9–48.6), p=0.219. Equivalence is unproven. 14

Sequential allocation, overlap with the 2022 cohort and nonstandardised prescribing limit comparison. Medication-free outcomes are exploratory; restricting analysis to successful eyes can bias it. One eye per group required repair for cyclodialysis/hypotony. Results report combined-group survival at 1/2/3 years as 0.768/0.692/0.692, whereas Discussion gives 1/0.750/0.435. Do not silently reconcile these. Patient count/eye dependence remain unclear. 14

Balance CPC mode, benefit and risks

Cyclophotocoagulation (CPC) acts on the ciliary body; continuous-wave, slow-coagulation and micropulse procedures are not interchangeable. The lecture uses a Cornelia-de-Lange teaching case to discuss high anaesthetic risk: micropulse first, a drainage implant later. This is not comparative efficacy evidence. Balance retreatment, inflammation, hypotony and visual potential; “last resort” is not universal for every mode and situation. 1 8

2024 primary study: micropulse versus continuous-wave CPC. Retrospective, two centres, under 18 years: 48 patients, 26 micropulse versus 30 continuous-wave eyes. One-year success 7/26 (26.9%) versus 13/30 (43.3%); survival analysis p=0.03. Definition: IOP 5–21 mmHg without further surgery or oral pressure-lowering medication; topical drops were allowed. Numerical survival CIs are not tabulated; the figure caption describes 95% confidence bands. 15

CW: one persistent hypotony and two eyes with prolonged inflammation requiring steroids. MP: one enucleation with pre-existing uncontrolled pressure/pain. All children received general anaesthesia. No reported visual-acuity/OCT endpoints. Surgeon selection, variable settings and unclear eye dependence in the main comparison limit causality. 15

CW baseline pressure: narrative 28.9±8.5, Table 1 instead 32.4±10.9. It also prints 5 (15.6%) despite 30 CW eyes. Do not resolve these discrepancies without clarification or claim universal safety superiority. 15

06Medication and safety boundaries

In PCG, medication often bridges to surgery or supplements it. For some secondary forms and JOAG, medical control may initially suffice. The old page confuses “<10% effectiveness” with “<10% pressure reduction”. The original export gives the latter but no verifiable study. Neither figure is adopted as an established general effect. 1 2 8

Carbonic anhydrase inhibitors (CAIs) can cause systemic metabolic acidosis; watch for poor feeding, failure to thrive and lethargy. Beta blockers can cause bradycardia, bronchospasm or respiratory depression. Premature infants and neonates are particularly vulnerable. Check product, concentration, age, weight, comorbidities and local prescribing information; this is not a general paediatric dosing schedule. 1 2

Brimonidine: distinguish contraindication from caution. The German Alphagan 0.2% (2 mg/ml) product information, March 2026, sections 4.2–4.4/4.8 specifies: contraindicated below 2 years, not recommended below 12; from 2 years use caution and close monitoring, especially at 2–7 years and/or ≤20 kg. No clinical trials were conducted at 12–17 years. 6

Take somnolence, hypotonia and breathing disturbance seriously. Being over 2 is not a general safety clearance. 6

Retain prostaglandin analogues, apraclonidine, pilocarpine and ROCK inhibitors. Effect, authorisation and risks differ by age and product. Export estimates of no response in 40–54% with beta blockers and 50–80% with prostaglandins lack an identified cohort. Operative pilocarpine use is not a universal prescription; isolated ROCK cases do not establish paediatric safety. 8

Explain instillation technique and systemic warning signs. Wiping excess fluid and instructed punctal occlusion can reduce absorption. Confirm pressure control through serial structure and visual development. Marked drowsiness or breathing problems require immediate medical assessment; do not wait for a routine visit. 2 6

07Guidance and lifelong follow-up

Read guidance in its historical and clinical context

DOG/BVA 15b “Frühkindliches Glaukom” dates to 20.12.1998. The text covers assessment up to the first operation. It is not a new S2k guideline or a rigid legal treatment protocol. Historical operative criteria, including >18–19 mmHg, are not a current standalone diagnostic threshold. Its follow-up intervals depend on findings. 3

AAO BCSC is a textbook chapter, not a paediatric PPP. Adult recommendations do not replace childhood source verification. 1 2 8 12

Follow pressure control and visual development

Review according to clinical need: symptoms, visual function, medication tolerance, pressure, cornea, disc, axial length and refraction. Display earlier values alongside current results. Adapt intervals and anaesthetic needs to age, risk, surgery and progression. Pressure elevation, reoperation or additional medication can occur after apparently successful surgery. 1 2

Coordinate cycloplegic refraction, optical correction and individually prescribed amblyopia treatment with orthoptics. Corneal scarring, anisometropia, strabismus, nystagmus, cataract and lens subluxation can further limit vision. Generic “visual exercises” do not replace treatment. A smaller cup after control does not mean lost nerve fibres have regenerated. 1 2 4

The export describes favourable courses with onset at 3–12 months and acuity >20/70 after >5 years, worse outcomes with neonatal onset or corneal diameter >14 mm, and sometimes 50% legal blindness or 50% no light perception in secondary groups. These heterogeneous figures need original tables and populations. They are not individual prognoses. Separate pressure control, amblyopia and vision. 8

Discussion includes drop timing, adult brimonidine effects and OHTS. It quotes risks of 36% versus 6% at IOP 25–27 mmHg with CCT <555 versus >588 µm, and discusses 28–30 mmHg in relation to retinal vein occlusion. Population, endpoint, time and exact tables need primary verification. 8

These adult figures are not childhood thresholds or treatment rules; detailed appraisal belongs in diagnostics and medication chapters. 8

General medication, laser and glaucoma-surgery chapters complement this lecture. Childhood-specific risks remain here; adult studies are not substitutes.

08Comparison table and recall questions

The eight rows summarise the lecture. Read the relevant chapters and sources for numbers and limitations. Questions support voluntary recall and do not constitute a clinical competency assessment.

8. Comparison table and recall questions
TopicFinding / meaningCheck / next stepLimit / pitfall
Corneal diameter≥11 mm newborn; >12 mm first year; >13 mm any ageCombine cornea, axial length, disc and serial findingsNormal diameter does not exclude glaucoma
Intraocular pressure>21 mmHg is part of combined criteriaRecord device, anaesthesia, cooperation and structureNo fixed 10–20% or CCT correction
BrimonidineContraindicated below 2: German product informationNot recommended below 12; special caution at 2–7 / ≤20 kgAge 2 alone is not a safety clearance
Surgical choiceGoniotomy ab interno; trabeculotomy ab externoPCG, view and anatomy guide selection11–15% / enhanced technique: exact source pending
Ahmed FP7 / FP8Plan size and position individuallyCheck current drawing against ocular dimensionsIFU 03/2025: FP7 16 mm/184 mm²; FP8 11 mm/102 mm²; AL <21 mm is not a verified rule
CHEDCloudy thick cornea; PCG may coexistSerial change, disc, axial length; UBM / Pentacam adjuncts1100–1200 µm not a threshold; CHED1 historical
AniridiaDo not equate glaucoma risk and WAGRAssess PAX6 / WT1 and tumour surveillance jointlyNo blanket 50% WAGR rule
Sturge-WeberAngle / episcleral venous pressure / choroidAssess mechanism, anaesthesia and surgical riskConsider choroidal effusion/haemorrhage with pressure fall
Why is one pressure reading insufficient?

Measurement conditions may mislead. Cornea, disc, axial length and serial findings must support interpretation.

How do you choose goniotomy versus trabeculotomy?

Both are options in PCG. Goniotomy generally requires a view; ab externo trabeculotomy can be used with opacity. There is no universal ranking for all children.

References and access status

  1. 1
    EGS — Terminology and Guidelines for Glaucoma, 6th edition (2025)

    Childhood pp 117–123 read in accessible full text; entire book not read. DOI 10.1136/bjophthalmol-2025-egsguidelines. also prints <21 mmHg on two occasions in the visually inspected PDF.

  2. 2
    WGA — Consensus 9: Childhood Glaucoma (2013)

    All online consensus points read; full book chapters not read. Expert consensus, not a new randomised trial.

  3. 3
    DOG/BVA — Leitlinie 15b: Frühkindliches Glaukom (20.12.1998)

    Complete official HTML read; historical scope up to first operation. Not a new S2k standard.

  4. 4
    Freedman et al. — IATS 10 years (2021), DOI 10.1001/jamaophthalmol.2020.5664

    Main article including methods, results, table and discussion read; supplement not read. Secondary analysis of IOL randomisation, not randomised glaucoma treatment.

  5. 5
    Gagrani, Garg, Ghate — Cochrane (2020), DOI 10.1002/14651858.CD008213.pub3

    Complete PubMed abstract and parts of PMC report read; not the entire review and appendices. Search to 27.04.2020, not 2026.

  6. 6
    Alphagan 0.2% (2 mg/ml) — German Fachinformation, March 2026

    German sections 4.1–4.4/4.8 directly read; relevant PDF pages visually checked. Not all six pages or the underlying trial fully appraised. Earlier UK source retained in access ledger. This resolves the earlier UK-only access gap for this product, not the review of other products.

  7. 7
    Weiss et al. — IC3D edition 3 (2024), DOI 10.1097/ICO.0000000000003420

    Introduction/classification change and CHED section inspected; not all 62 pages read. CHED1 is historical nomenclature.

  8. 8
    Al-Sheikha — Glaucoma in Children (original lecture)

    Complete locally exported Arabic text read; automated transcription may contain errors. Video, slides and image tables not fully inspected. Cases are teaching observations, not treatment recommendations. Retain the original terms. The Studio text reduced this to “creating a Window-Defect”. All original topics and eight comparison rows are retained. Outstanding primary sources and dictionary entries are listed in the source record; this draft is not approved for publication.

  9. 9
    CGRN — Anomaly Algorithm and Classification System (2024)

    Complete one-page 2024 algorithm visually read, not original2013 chapter. Reproducible pressure >21; apparent mmHg typo for corneal diameter not propagated.

  10. 10
    Noureddin et al. — Viscocanalostomy versus trabeculotomy (2006)

    Abstract excerpt inspected; original tables/full text pending. Pilot comparison in eight bilaterally affected children. Abstract excerpt inspected; full text pending.

  11. 11
    New World Medical — Ahmed FP7 / FP8 IFUs, Rev B 03/2025

    Both IFUs downloaded; English/German description and indication read, German dimension drawings p 17 visually checked. Not every language or manufacturer-cited study read. Keep historical model values separate.

  12. 12
    AAO — BCSC 2024–2025, Section 10, Chapter 11, pp 187–217

    Complete local chapter text export read. Original PDF/table images not visually inspected. P219 starts Chapter12. Current 2026–2027 catalogue read; current chapter text unavailable. Textbook, not paediatric PPP. Individual counselling requires pedigree and variant assessment; the underlying genetic primary source was not read. EGS6 (2025) childhood text pp 117–123 and the WGA 2013 online consensus points were read, not the complete books. AAO BCSC 2024–2025 is now identified: Section 10, Chapter 11, pp 187–217; p 219 starts the general medication chapter. The complete local chapter text export was read; the original PDF and figures were not visually inspected. This is a textbook chapter, not a paediatric PPP. The current AAO catalogue lists 2026–2027; its chapter text is unavailable here. Adult recommendations do not replace childhood source verification.

  13. 13
    WHO EMRO — Unified Medical Dictionary

    Actually inspected entries listed in terminology-ledger.md; other translations explicitly provisional.

  14. 14
    Vahedian et al. — refractory PCG comparison (2026), DOI 10.1186/s12886-026-05292-9

    Entire main narrative read; table bodies, figure pixels and two supplements unread. Nonrandomised; secondary outcomes exploratory; conflicting survival numbers documented. Main text read; table bodies and supplements unread.

  15. 15
    Wang et al. — paediatric MPCPC versus CWCPC (2024), DOI 10.1371/journal.pone.0291247

    Entire main narrative read; Table1 inspected in official XML. Supplement and figure pixels unread. Retrospective, two centres; internal numerical discrepancies recorded. Main text and Table 1 read; supplement and figure pixels not inspected.

  16. 16
    Alsheikheh et al. — Long-term results of surgery in childhood glaucoma (2007), DOI 10.1007/s00417-006-0415-2

    Complete publisher abstract directly read; retrospective, no full-text/table appraisal. The 72.1% concerns medication after the final operation, not freedom from surgery. Complete publisher abstract read, full text/tables unread; no confidence intervals in abstract and no controlled procedure ranking.

  17. 17
    Margeta et al. — Staying away from the optic nerve (2017), DOI 10.1016/j.jaapos.2016.09.027

    Complete PubMed abstract directly read. Anatomical derivation/validation, not clinical comparative evidence; main text and formula unread. Complete abstract read; formula, main text and supplement unread.

Original lecture links